ABN AMRO Bank N.V. purchased a new stake in Ventas, Inc. (NYSE:VTR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 110,040 shares of the real estate investment trust's stock, valued at approximately $9,788,000.
Other large investors have also bought and sold shares of the company. Deutsche Bank AG increased its stake in shares of Ventas by 0.7% during the 4th quarter. Deutsche Bank AG now owns 3,904,293 shares of the real estate investment trust's stock worth $302,114,000 after purchasing an additional 27,688 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Ventas by 2.5% in the 4th quarter. Bank of New York Mellon Corp now owns 2,868,962 shares of the real estate investment trust's stock valued at $222,000,000 after acquiring an additional 70,459 shares during the period. Norges Bank bought a new stake in shares of Ventas in the fourth quarter valued at approximately $474,571,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Ventas by 7.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,346,111 shares of the real estate investment trust's stock valued at $104,095,000 after buying an additional 92,236 shares in the last quarter. Finally, Cbre Investment Management Listed Real Assets LLC lifted its stake in shares of Ventas by 5.8% during the 4th quarter. Cbre Investment Management Listed Real Assets LLC now owns 1,851,968 shares of the real estate investment trust's stock valued at $143,305,000 after buying an additional 101,370 shares in the last quarter. 94.18% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Ventas
In other Ventas news, Director Michael J. Embler purchased 2,500 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average cost of $78.81 per share, with a total value of $197,025.00. Following the transaction, the director directly owned 19,202 shares in the company, valued at approximately $1,513,309.62. The trade was a 14.97% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.53% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the stock. The Goldman Sachs Group reiterated a "buy" rating and issued a $110.00 price objective on shares of Ventas in a research note on Tuesday, May 19th. Raymond James Financial began coverage on Ventas in a research note on Tuesday, June 16th. They issued an "outperform" rating and a $94.00 target price on the stock. KeyCorp raised their price target on Ventas from $90.00 to $95.00 and gave the company an "overweight" rating in a report on Thursday, May 7th. Citigroup lifted their price target on Ventas from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada boosted their price objective on Ventas from $98.00 to $99.00 and gave the stock an "outperform" rating in a report on Friday. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.
Read Our Latest Analysis on VTR
Ventas Stock Up 1.3%
NYSE VTR opened at $91.48 on Friday. Ventas, Inc. has a 1 year low of $66.38 and a 1 year high of $101.60. The company has a debt-to-equity ratio of 0.86, a current ratio of 0.44 and a quick ratio of 0.44. The business's 50-day moving average is $90.45 and its 200 day moving average is $86.54. The stock has a market capitalization of $46.92 billion, a PE ratio of 169.40, a PEG ratio of 2.11 and a beta of 0.69.
Ventas Profile
(
Free Report)
Ventas, Inc NYSE: VTR is a real estate investment trust (REIT) that specializes in healthcare-related real estate. The company acquires, owns and manages a diversified portfolio of properties serving the healthcare continuum, including senior housing communities, skilled nursing facilities, medical office buildings, life science and research centers, and other properties leased to healthcare providers and operators. Ventas generates revenue through long-term leases, property management and selective development activities focused on meeting the real estate needs of the healthcare sector.
Ventas' business model combines property ownership with active asset management and capital markets activity.
Recommended Stories
Want to see what other hedge funds are holding VTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventas, Inc. (NYSE:VTR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ventas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventas wasn't on the list.
While Ventas currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.